Samarium-153 treatment optimized for longer-lasting relief of end-stage cancer bone pain

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, two-part phase 1 study of TLX090-Tx (153Sm-DOTMP) given to patients with painful metastatic bone lesions to characterize safety, pharmacokinetics, and radiation dosimetry and to collect early signals of pain relief. Participants must have histologically confirmed malignancy with multiple bone metastases including at least one painful osteoblastic lesion identified on a 99mTc-diphosphonate bone scan and have progressed on or be ineligible for other anticancer treatments or palliative external beam radiotherapy. Key data collected will include drug and radiation distribution, kidney and blood counts monitoring, and changes in patient-reported pain scores and analgesic use. Dosing and follow-up occur at specialized nuclear medicine centers with eligibility requiring adequate renal and hematologic function per protocol.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants have had disease progression while on anti-cancer treatment, and are not eligible for the treatments, or their lesions are not amenable to palliative EBRT.
* Participants must have a histologically confirmed diagnosis of malignancy at any time prior to their participation in this clinical trial with multiple metastatic bone lesions with at least 1 metastatic painful osteoblastic tumor that causes a minimum pain score of 4 on the NRS11.
* Participants must have bone cancer in one or more skeletal locations as identified by a 99mTc-diphosphonate bone scan within 60 days of dosing. At least one lesion must be osteoblastic. If described as osteosclerotic, radiology confirmation that the lesion is osteoblastic is required. Adequate organ function, including:
* Renal function, defined as a measured creatinine clearance (CrCl) ≥30 mL/min as per Cockroft Gault or based on radioisotope glomerular filtration rate (GFR).
* Hematologic function, defined as a platelet count of \>100,000 cells/mm3 and an Absolute neutrophil count (ANC) of \>1000 cells/mm3.
* Hemoglobin ≥8 g/dL.
* Liver function:
* Total bilirubin ≤1.5 × the upper limit of normal (ULN).
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5 × ULN with participants with known liver metastases.
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3 × ULN with participants with Gilbert's Syndrome.
* Life expectancy of at least 16 weeks from the date of study drug administration (Day 1).
* Karnofsky performance status \>60%, assessed during the screening period prior to study drug administration.

Exclusion Criteria:

* Participants are pregnant or breastfeeding.
* Participants who have received maximum tolerable radiation to the spinal cord, have untreated pathologic bone fracture, spinal cord compression, unstable spine, or imminent long bone fracture.
* Participants with a bone scan pattern showing diffuse, intense skeletal uptake with absent or faint kidney / bladder activity, typically indicating widespread bone metastases or high bone turnover from metabolic or hematologic diseases (Superscan) pattern on Technetium 99-m bone scan scintigraphy - defined as diffusely increased skeletal uptake with absent or markedly reduced renal and soft tissue visualization - are excluded from the study.
* Participants with impending or suspected or at high risk for spinal cord compression.
* Participants with neurogenic pain or significant pain associated with soft tissue lesions or other pain that, in the opinion of the Investigator, might interfere with the assessment of pain relief for bone tumors.
* Participants who require surgery over their trial period that would require pain medication or analgesia.
* Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product.
* History of unstable angina (defined as angina at rest) or new-onset angina diagnosed within the 3 months prior to screening.
* History of myocardial infarction within 3 months prior to screening, as determined by medical history / Baseline ECG.
* Uncontrolled cardiac arrhythmias (≥Grade 3 CTCAE version 5.0) or any history of ≥Grade 3 arrhythmia.
* Congestive heart failure ≥New York Heart Association Class 2.
* Clinically significant abnormalities on ECG at screening including corrected QT interval (Fridericia's formula) \>450 msec for males or 470 msec for females at screening.
* Inability to complete the needed investigational and standard imaging examinations due to any reason (eg, severe claustrophobia, inability to lie still for the entire imaging time).
* Presence of any other condition that may increase the risk associated with study participation or interfere with the interpretation of study results, and, in the opinion of the study Investigator, would make the participant inappropriate for entry into the study.
* Participants with active infections (human immunodeficiency virus, human papillomavirus. Hepatitis A, Hepatitis B, and Hepatitis C).

Where it's running

• Biogenix Molecular, LLC, CIRA Health
  Miami, Florida, United States Recruiting
• NovaCure
  Miami, Florida, United States Recruiting
• Houston Metro Urology
  Houston, Texas, United States Recruiting
• Oncology Consultants
  Houston, Texas, United States Recruiting
• Excel Diagnostics and Nuclear Oncology Center
  Houston, Texas, United States Recruiting
• University of Texas Medical Branch at Galveston (UTMB)
  Houston, Texas, United States Recruiting

Study contacts

• Study coordinator: Sahar Khan
• Email: sahar.khan@telixpharma.com
• Phone: 248-469-2985

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preventing G-CSF bone pain with diosmin-hesperidin and loratadine

  We will test whether diosmin-hesperidin, loratadine, or both can prevent bone pain from G-CSF in adults with leukemia or lymphoma.

  Recruiting Alexandria University · Alexandria · NCT07300735

• Optimizing radioactive seed implantation for spinal and bone metastases with combined treatment planning and biomechanical simulation

  This trial tries adding patient-specific biomechanical simulation to standard treatment planning to see if radioactive seed implantation gives better pain control and fewer complications for adults with painful or progressive bone metastases.

  Recruiting Jinan Military General Hospital · Jinan, Shandong · NCT07171996

• Radiofrequency ablation and bone augmentation plus radiotherapy vs radiotherapy alone for spinal metastases

  This trial will test whether adding radiofrequency ablation and bone augmentation to radiotherapy helps people with metastatic spine disease (T5-L5) have fewer skeletal-related events and less pain.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07090122

• Targeted radiotherapy (SFRT or SCART) for bone metastases with soft-tissue tumors

  This study will test whether two advanced radiation methods (SFRT or SCART) shrink the soft-tissue part of bone metastases better than conventional radiotherapy in adults with advanced cancer.

  Recruiting Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06987370

• Early palliative care consultation for people with bone metastases referred for radiotherapy

  This trial will test if offering an early hospital palliative care consultation improves quality of life and satisfaction for adults with advanced cancer and bone metastases who are referred for palliative radiotherapy.

  Recruiting at 5 sites Phase 2 UMC Utrecht · Amersfoort and 4 other locations · NCT06805396

• Low-dose radiotherapy for painful bone metastases in multiple myeloma patients

  This study is testing if low-dose radiation therapy can help reduce bone pain in patients with multiple myeloma that has spread to their bones.

  Recruiting at 9 sites University of Southern California · Duarte, California and 8 other locations · NCT03858205

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.